EP4259138A4 - METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE - Google Patents
METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE Download PDFInfo
- Publication number
- EP4259138A4 EP4259138A4 EP21904143.1A EP21904143A EP4259138A4 EP 4259138 A4 EP4259138 A4 EP 4259138A4 EP 21904143 A EP21904143 A EP 21904143A EP 4259138 A4 EP4259138 A4 EP 4259138A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- trimetazidine
- methods
- heart disease
- modified forms
- treating heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063123715P | 2020-12-10 | 2020-12-10 | |
US202063123728P | 2020-12-10 | 2020-12-10 | |
US202063123721P | 2020-12-10 | 2020-12-10 | |
US202063123711P | 2020-12-10 | 2020-12-10 | |
PCT/US2021/061583 WO2022125370A1 (en) | 2020-12-10 | 2021-12-02 | Methods of treating heart conditions using modified forms of trimetazidine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4259138A1 EP4259138A1 (en) | 2023-10-18 |
EP4259138A4 true EP4259138A4 (en) | 2024-11-06 |
Family
ID=82932763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21904143.1A Pending EP4259138A4 (en) | 2020-12-10 | 2021-12-02 | METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4259138A4 (en) |
WO (1) | WO2022125370A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020243120A1 (en) * | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Methods of treating fibrosis using compounds that promote glucose oxidation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107530337B (en) * | 2014-12-22 | 2021-07-09 | 贝克心脏与糖尿病研究所 | treatment method |
EP3419666A4 (en) * | 2016-02-26 | 2019-10-09 | The Regents of The University of California | AGONISTIC THERAPY OF ALPHA-1-ADRENERGIC RECEPTORS |
EP3866794B1 (en) * | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
US20220249463A1 (en) * | 2019-05-31 | 2022-08-11 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
US20220226313A1 (en) * | 2019-06-03 | 2022-07-21 | Imbria Pharmaceuticals, Inc. | Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinase |
-
2021
- 2021-12-02 EP EP21904143.1A patent/EP4259138A4/en active Pending
- 2021-12-02 WO PCT/US2021/061583 patent/WO2022125370A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020243120A1 (en) * | 2019-05-31 | 2020-12-03 | Imbria Pharmaceuticals, Inc. | Methods of treating fibrosis using compounds that promote glucose oxidation |
Non-Patent Citations (4)
Title |
---|
BERLINER DOMINIK ET AL: "The Treatment of Heart Failure with Reduced Ejection Fraction", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, 22 May 2020 (2020-05-22), XP093206987, ISSN: 1866-0452, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643567/pdf/Dtsch_Arztebl_Int-117_0376.pdf> DOI: 10.3238/arztebl.2020.0376 * |
KLONER ROBERT A. ET AL: "Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 9, no. 3, 4 February 2020 (2020-02-04), XP093207112, ISSN: 2047-9980, Retrieved from the Internet <URL:https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.015502> DOI: 10.1161/JAHA.119.015502 * |
MARON MARTIN S ET AL: "Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 12, 21 March 2016 (2016-03-21), pages 1399 - 1409, XP029469187, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2016.01.023 * |
See also references of WO2022125370A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022125370A1 (en) | 2022-06-16 |
EP4259138A1 (en) | 2023-10-18 |
WO2022125370A8 (en) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3697400A4 (en) | METHOD OF USING EHMT2 INHIBITORS TO TREAT OR PREVENT BLOOD DISEASES | |
EP3745862A4 (en) | METHOD OF TREATMENT OF FIBROTIC DISEASES | |
EP3958869A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF LUNG DISEASE RELATED TO BIOFILM | |
EP3932404A4 (en) | METHODS OF TREATMENT OF FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | |
EP3565540A4 (en) | METHODS FOR TREATMENT OF CARDIAC DISEASES | |
EP3752161A4 (en) | METHOD OF TREATMENT OF FIBROSE | |
EP4248212A4 (en) | METHODS OF TREATING DISEASES AND DISORDERS | |
EP3664789A4 (en) | METHODS OF TREATMENT OF DISEASES AND NERVE INJURY | |
EP4168036A4 (en) | ACTRII-ALK4 ANTAGONISTS AND METHODS FOR THE TREATMENT OF HEART FAILURE | |
EP3746067A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY EDEMA OR PUNGI | |
EP4313297A4 (en) | LACTOYLAMINO ACIDS FOR THE TREATMENT OF METABOLIC DISEASES | |
EP4232039A4 (en) | METHODS OF TREATING LUNG CANCER | |
EP3826649A4 (en) | METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS | |
EP4138900A4 (en) | METHODS OF TREATING CERVICAL CANCER | |
EP4301410A4 (en) | METHODS FOR TREATMENT OF THYROID EYE DISEASE | |
EP3833377A4 (en) | METHODS OF TREATMENT OF NEUROFIBROMATOSE TYPE 1 AND RELATED ALKALINE PHOSPHATASE DISEASES | |
EP4262814A4 (en) | METHODS OF TREATING CASTOR-RELATED DISORDERS | |
EP4229828A4 (en) | METHODS OF TREATING FIBROSIS | |
EP4125965A4 (en) | METHOD FOR TREATING LUNG DISEASES WITH CELL-FREE AMBULANCE | |
EP4259138A4 (en) | METHODS OF TREATING HEART DISEASE WITH MODIFIED FORMS OF TRIMETAZIDINE | |
EP4146273A4 (en) | METHOD OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | |
EP4003399A4 (en) | METHODS OF PREVENTING OR TREATMENT OF FATTY ACID DEGENERATION OF SKELETON MUSCLES | |
EP3914589A4 (en) | METHODS OF TREATMENT OF DISEASES WITH MAGL INHIBITORS | |
EP3840743A4 (en) | HYGROMYCIN-A COMPOUNDS AND METHODS OF TREATMENT OF SPIROCHETARY DISEASES | |
EP3914203A4 (en) | METHODS OF TREATMENT OF OBSTRUCTIVE SLEEP APNEA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231221 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20241008 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 295/088 20060101ALI20241001BHEP Ipc: A61K 31/497 20060101ALI20241001BHEP Ipc: C07D 213/80 20060101ALI20241001BHEP Ipc: C07D 401/12 20060101ALI20241001BHEP Ipc: C07D 241/04 20060101ALI20241001BHEP Ipc: C07D 241/02 20060101ALI20241001BHEP Ipc: A61P 9/00 20060101ALI20241001BHEP Ipc: A61K 31/496 20060101ALI20241001BHEP Ipc: A61K 31/495 20060101ALI20241001BHEP Ipc: A61K 31/455 20060101AFI20241001BHEP |